harmacoeconomics identifies, measures and compares antimicrobials. Among aminopenicillins, Wymox was the the costs, and consequences of pharmaceutical costliest brand of amoxycillin 500 mg with 182.58% higher products and services. [1] High cost of medicines has economic price than the average price. Similarly, Lyser-A plus has 126.9% implications for the patients and patient compliance may be higher rate than the average price of amoxycillin 250 mg significantly dependent on the cost of medicines prescribed.
capsules. Ampilin (28.65% higher) and Synthocillin (26.23% In addition to the confusing brand names of various medicines higher) were the costliest brands of ampicillin 250 mg and in the Indian market, [2] price variation poses a dilemma for 500 mg respectively. The ampicillin-cloxacillin combination practicing doctors. In case of many medicines there is a wide Duoclox was the cheapest brand. Cefixime showed the difference in the prices between different brands, which could maximum price variation among the cephalosporins. Virexim be twofold to more than 100-fold.
[3] It is not always easy for was one of the cheapest 200 mg brands and CTAX-O was the the practitioner to decide which brand to prescribe by merely costliest with 132.25% higher price than the average. Among considering the medicine price.
fluoroquinolones, the maximum variation in prices was in
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the two strengths of ofloxacin viz. Tarivid, the prices of which
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PubMed ID P Antimicrobials are commonly prescribed medicines. We compared the price of some branded antimicrobials to find their price difference when compared to the average price.
The prices of the available antimicrobial brands were downloaded from the IDR site (IDRMedCLIK@MedCLIK. com). Brands of 20 most commonly used oral antimicrobials were selected and their maximum retail price (MRP) without addition of local taxes was used for comparison. Average price for an antimicrobial was calculated by adding the price of all its brands studied, divided by the number of brands. The minimum and maximum price for each antimicrobial formulation of same concentration was noted and percentage variation in price was calculated from the average price. 5 and Oflomil (400 mg) was priced at Rs. 53. The deviation of price was more than 300% towards the higher side as compared to the average prices of both strengths. Azithromycin brands also showed more than 150% variation on the higher side as compared to the average price, with Vicon costing Rs. 234.89 as compared to the average price of Rs. 91.87.
Discussion
Our findings reveal that the prices of various antimicrobial brands show great variation with the difference being from 95% lesser to more than 350% higher than the average price. The mean price was considered to be the most appropriate price remuneration to a pharmacist for stocking only their higher priced item rather than generics.
[7]
In India, in 1979, 80-85% of the drugs in the market were under c) Literate patients through word of mouth get to know about price control. The number has slowly decreased and by 2002 cheaper brands of medicine and change the brand on their only 15-20% drugs were under price control.
[4] The common own. This may result in variation in bioavailability and man therefore has to shell out more money with medicine response. [8] prices spinning out of his reach. d) Smaller private pharmacies usually stock only a few brands, forcing the patients to choose from these. [6] The clinicians in addition to remembering the pharmacological e) Patients may be noncompliant to the expensive brands and and trade names also have to remember the prices of various take a lesser dose to save money without realizing that brands. There is a general feeling that a very low-priced drug reduced dosage will decrease the therapeutic response. although affordable may not fulfill the bioavailability standards expected of a good brand and a high-priced drug could be better. However, pricing does not give any assurance of the product's quality, although most of the companies are careful about quality control.
[5]
The implications of such price differences are: a) With over 64,000 brands of various medicines being sold in the market, the doctor has a big range to choose from. Medical representatives vie for his prescription and decision-making is difficult. [6] b) It is reported that the pharmacists do not dispense the same brand as prescribed by the doctor and try to substitute it with other alternatives, quoting the reason of nonavailability. This is often done with vested interest for economic gains as some brands have a higher profit margin.
Interaction with leading practitioners confirms this point. f) Lesser known companies are known to price their products lower than well-established brands to promote their product economically thus indirectly aiding the doctors to prescribe cheaper versions. The medical representatives try to push their products using incentives.
[7] Also, most of the pharmacies are forced to sell the drugs at a very lean margin as a neighbor pharmacist may sell the same for a good undercut in prices. [8] Currently, very few medicines are under drug prices control order. [9] Hence it is desired that the Government should bring all lifesaving and essential medicines under price control. A company with an innovator brand may be allowed to have a higher reasonable margin. Bioequivalence reports comparing the marketed brand with the innovator brand should be made mandatory. The current practice of adding taxes on the printed MRP should be stopped and the prices should be standardized by incorporating the applicable sales tax so that the customers will not be subjected to price variation in the same medicine brands across the country. [9] Organizations like low cost standard therapeutics have suggested that all brand names should be abolished and medicines should be sold only under generic names. This would also decrease the possibility of medication errors due to look-alike and sound-alike brands.
[2]
The medical practitioners have to keep in mind the link interventions seem too farfetched in the Indian context. It is recommended that the appraisal and management of marketed drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences. [13] 
